Michelle Nicole Messmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle Nicole Messmer has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Robert Julian Binder
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3 shared publications Yu Jerry Zhou
Authors' Affiliation: Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
3 shared publicationsColleen S. Netherby
2 shared publications- Scott I. Abrams
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
2 shared publications - Shabaana Abdul Khader
Department of Microbiology, The University of Chicago
2 shared publications Yinyao Lin
2 shared publications
Latest Publications
- Top Cited Papers
- 7 June 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (36)
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity
Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3+ cDC1− and CD8+ leukocyte–dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.
- 7 June 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (36)
Top Cited PapersIntratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity
Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3+ cDC1− and CD8+ leukocyte–dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.
- 1 September 2018
- Published by Oxford University Press (OUP)
Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer
The immune system serves as an integral checkpoint to developing malignancies. However, when cancer ultimately becomes detectable, this implicates an inherent failure of effective immune control. One constant theme in cancer biology has been the ability of these “diseases,” in particular, ovarian cancer, to compromise immune-mediated mechanisms of neoplastic control. These empirical observations have subsequently laid the scientific foundation to investigate ways in which the immune system can be reengaged as a powerful therapeutic weapon, singly or in combination with other modalities. This field has been coined “cancer immunotherapy” and, importantly, strong progress has been made to date to justify its feasibility and potential merit. This chapter focuses on the fundamental immunologic principles that have guided the development of the cancer immunotherapy concept, as well as details both the successes and the limitations of cancer immunotherapy in patients with metastatic ovarian cancer.
- 1 September 2018
- Published by Oxford University Press (OUP)
Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer
The immune system serves as an integral checkpoint to developing malignancies. However, when cancer ultimately becomes detectable, this implicates an inherent failure of effective immune control. One constant theme in cancer biology has been the ability of these “diseases,” in particular, ovarian cancer, to compromise immune-mediated mechanisms of neoplastic control. These empirical observations have subsequently laid the scientific foundation to investigate ways in which the immune system can be reengaged as a powerful therapeutic weapon, singly or in combination with other modalities. This field has been coined “cancer immunotherapy” and, importantly, strong progress has been made to date to justify its feasibility and potential merit. This chapter focuses on the fundamental immunologic principles that have guided the development of the cancer immunotherapy concept, as well as details both the successes and the limitations of cancer immunotherapy in patients with metastatic ovarian cancer.
- 29 November 2014
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 64 (1) , 1-13
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Immune function relies on an appropriate balance of the lymphoid and myeloid responses. In the case of neoplasia, this balance is readily perturbed by the dramatic expansion of immature or dysfunctional myeloid cells accompanied by a reciprocal decline in the quantity/quality of the lymphoid response. In this review, we seek to: (1) define the nature of the atypical myelopoiesis observed in cancer patients and the impact of this perturbation on clinical outcomes; (2) examine the potential mechanisms underlying these clinical manifestations; and (3) explore potential strategies to restore normal myeloid cell differentiation to improve activation of the host antitumor immune response. We posit that fundamental alterations in myeloid homeostasis triggered by the neoplastic process represent critical checkpoints that govern therapeutic efficacy, as well as offer novel cellular-based biomarkers for tracking changes in disease status or relapse.
- 29 November 2014
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 64 (1) , 1-13
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Immune function relies on an appropriate balance of the lymphoid and myeloid responses. In the case of neoplasia, this balance is readily perturbed by the dramatic expansion of immature or dysfunctional myeloid cells accompanied by a reciprocal decline in the quantity/quality of the lymphoid response. In this review, we seek to: (1) define the nature of the atypical myelopoiesis observed in cancer patients and the impact of this perturbation on clinical outcomes; (2) examine the potential mechanisms underlying these clinical manifestations; and (3) explore potential strategies to restore normal myeloid cell differentiation to improve activation of the host antitumor immune response. We posit that fundamental alterations in myeloid homeostasis triggered by the neoplastic process represent critical checkpoints that govern therapeutic efficacy, as well as offer novel cellular-based biomarkers for tracking changes in disease status or relapse.
Mild cold‐stress depresses immune responses: Implications for cancer models involving laboratory mice
Physiologically accurate mouse models of cancer are critical in the pre‐clinical development of novel cancer therapies. However, current standardized animal‐housing temperatures elicit chronic cold‐associated stress in mice, which is further increased in the presence of tumor. This cold‐stress significantly impacts experimental outcomes. Data from our lab and others suggest standard housing fundamentally alters murine physiology, and this can produce altered immune baselines in tumor and other disease models. Researchers may thus underestimate the efficacy of therapies that are benefitted by immune responses. A potential mediator, norepinephrine, also underlies stress pathways common in mice and humans. Therefore, research into mechanisms connecting cold‐stress and norepinephrine signaling with immune depression in mice could highlight new combination therapies for humans to simultaneously target stress while stimulating anti‐tumor immunity.
Mild cold‐stress depresses immune responses: Implications for cancer models involving laboratory mice
Physiologically accurate mouse models of cancer are critical in the pre‐clinical development of novel cancer therapies. However, current standardized animal‐housing temperatures elicit chronic cold‐associated stress in mice, which is further increased in the presence of tumor. This cold‐stress significantly impacts experimental outcomes. Data from our lab and others suggest standard housing fundamentally alters murine physiology, and this can produce altered immune baselines in tumor and other disease models. Researchers may thus underestimate the efficacy of therapies that are benefitted by immune responses. A potential mediator, norepinephrine, also underlies stress pathways common in mice and humans. Therefore, research into mechanisms connecting cold‐stress and norepinephrine signaling with immune depression in mice could highlight new combination therapies for humans to simultaneously target stress while stimulating anti‐tumor immunity.
- Open Access
- 1 March 2014
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 2 (3) , 217-228
Establishment of Tumor-Associated Immunity Requires Interaction of Heat Shock Proteins with CD91
Host antitumor adaptive immune responses are generated as a result of the body's immunosurveillance mechanisms. How the antitumor immune response is initially primed remains unclear, given that soluble tumor antigens generally are quantitatively insufficient for cross-priming and tumors generally lack the classical pathogen-associated molecular patterns to activate costimulation and initiate cross-priming. We explored the interaction of the tumor-derived heat shock proteins (HSP) with their common receptor (CD91) on antigen-presenting cells (APC) as a mechanism for host-priming of T-cell–mediated antitumor immunity. Using targeted genetic disruption of the interaction between HSPs and CD91, we demonstrated that specific ablation of CD91 in APCs prevented the establishment of antitumor immunity. The antitumor immunity was also inhibited when the transfer of tumor-derived HSPs to APCs was prevented using an endogenous inhibitor of CD91. Inhibition was manifested in a reduction of cross-presentation of tumor-derived antigenic peptides in the lymph nodes, providing a molecular basis for the observed immunity associated with tumor development. Our findings demonstrate that early in tumor development, the HSP-CD91 pathway is critical for the establishment of antitumor immunity. Cancer Immunol Res; 2(3); 217–28. ©2013 AACR.
- 1 March 2014
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 2 (3) , 217-228
Open AccessEstablishment of Tumor-Associated Immunity Requires Interaction of Heat Shock Proteins with CD91
Host antitumor adaptive immune responses are generated as a result of the body's immunosurveillance mechanisms. How the antitumor immune response is initially primed remains unclear, given that soluble tumor antigens generally are quantitatively insufficient for cross-priming and tumors generally lack the classical pathogen-associated molecular patterns to activate costimulation and initiate cross-priming. We explored the interaction of the tumor-derived heat shock proteins (HSP) with their common receptor (CD91) on antigen-presenting cells (APC) as a mechanism for host-priming of T-cell–mediated antitumor immunity. Using targeted genetic disruption of the interaction between HSPs and CD91, we demonstrated that specific ablation of CD91 in APCs prevented the establishment of antitumor immunity. The antitumor immunity was also inhibited when the transfer of tumor-derived HSPs to APCs was prevented using an endogenous inhibitor of CD91. Inhibition was manifested in a reduction of cross-presentation of tumor-derived antigenic peptides in the lymph nodes, providing a molecular basis for the observed immunity associated with tumor development. Our findings demonstrate that early in tumor development, the HSP-CD91 pathway is critical for the establishment of antitumor immunity. Cancer Immunol Res; 2(3); 217–28. ©2013 AACR.
- 15 October 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 191 (8) , 4456-4465
Identification of the Cellular Sentinels for Native Immunogenic Heat Shock Proteins In Vivo
Select members of the heat shock proteins (HSPs) family, such as gp96, elicit immune responses specific to their chaperoned peptides. Although immunologic effects of HSPs on APCs described to date have largely been demonstrated with cell lines or primary cells in culture, their collective responses in vitro have been consistent with priming immune responses. In this study, we examine the physiologically relevant APCs in mice that are targeted after vaccination with native, murine HSPs, and we characterize those cells. Gp96 accesses the subcapsular region of the draining lymph node, and it is internalized predominantly by CD11b+ cells in this locale. Cells acquiring gp96 can transfer protective antitumor immunity to naive mice by actively cross-presenting gp96-chaperoned peptides and providing costimulation. Our studies illustrate how HSPs act to alert the immune system of cellular damage and will be of paramount importance in immunotherapy of patients with cancer and infectious disease.
- 15 October 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 191 (8) , 4456-4465
Identification of the Cellular Sentinels for Native Immunogenic Heat Shock Proteins In Vivo
Select members of the heat shock proteins (HSPs) family, such as gp96, elicit immune responses specific to their chaperoned peptides. Although immunologic effects of HSPs on APCs described to date have largely been demonstrated with cell lines or primary cells in culture, their collective responses in vitro have been consistent with priming immune responses. In this study, we examine the physiologically relevant APCs in mice that are targeted after vaccination with native, murine HSPs, and we characterize those cells. Gp96 accesses the subcapsular region of the draining lymph node, and it is internalized predominantly by CD11b+ cells in this locale. Cells acquiring gp96 can transfer protective antitumor immunity to naive mice by actively cross-presenting gp96-chaperoned peptides and providing costimulation. Our studies illustrate how HSPs act to alert the immune system of cellular damage and will be of paramount importance in immunotherapy of patients with cancer and infectious disease.
- Open Access
- 19 November 2012
- Published by Wiley in Autoimmune Diseases
- Vol. 2012, 1-11
CD91-Dependent Modulation of Immune Responses by Heat Shock Proteins: A Role in Autoimmunity
Heat shock proteins (HSPs) have been known for decades for their ability to protect cells under stressful conditions. In the 1980s a new role was ascribed for several HSPs given their ability to elicit specific immune responses in the setting of cancer and infectious disease. These immune responses have primarily been harnessed for the immunotherapy of cancer in the clinical setting. However, because of the ability of HSPs to prime diverse immune responses, they have also been used for modulation of immune responses during autoimmunity. The apparent dichotomy of immune responses elicited by HSPs is discussed here on a molecular and cellular level. The potential clinical application of HSP-mediated immune responses for therapy of autoimmune diseases is reviewed.
- 19 November 2012
- Published by Wiley in Autoimmune Diseases
- Vol. 2012, 1-11
Open AccessCD91-Dependent Modulation of Immune Responses by Heat Shock Proteins: A Role in Autoimmunity
Heat shock proteins (HSPs) have been known for decades for their ability to protect cells under stressful conditions. In the 1980s a new role was ascribed for several HSPs given their ability to elicit specific immune responses in the setting of cancer and infectious disease. These immune responses have primarily been harnessed for the immunotherapy of cancer in the clinical setting. However, because of the ability of HSPs to prime diverse immune responses, they have also been used for modulation of immune responses during autoimmunity. The apparent dichotomy of immune responses elicited by HSPs is discussed here on a molecular and cellular level. The potential clinical application of HSP-mediated immune responses for therapy of autoimmune diseases is reviewed.
- Open Access
- 1 May 2012
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (3) , 287-357
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity
Dendritic cell (DC) immunotherapy has shown a promising ability to promote anti-tumor immunity in vitro and in vivo. Many trials have tested single epitopes and single antigens to activate single T cell specificities, and often CD8+ T cells only. We previously found that determinant spreading and breadth of antitumor immunity correlates with improved clinical response. Therefore, to promote activation and expansion of polyclonal, multiple antigen-specific CD8+ T cells, as well as provide cognate help from antigen-specific CD4+ T cells, we have created an adenovirus encoding three full length melanoma tumor antigens (tyrosinase, MART-1 and MAGE-A6, “AdVTMM”). We previously showed that adenovirus (AdV)-mediated antigen engineering of human DC is superior to peptide pulsing for T cell activation, and has positive biological effects on the DC, allowing for efficient activation of not only antigen-specific CD8+ and CD4+ T cells, but also NK cells. Here we describe the cloning and testing of “AdVTMM2,” an E1/E3-deleted AdV encoding the three melanoma antigens. This novel three-antigen virus expresses mRNA and protein for all antigens, and AdVTMM-transduced DC activate both CD8+ and CD4+ T cells which recognize melanoma tumor cells more efficiently than single antigen AdV. Addition of physiological levels of interferon-α (IFNα) further amplifies melanoma antigen-specific T cell activation. NK cells are also activated, and show cytotoxic activity. Vaccination with multi-antigen engineered DC may provide for superior adaptive and innate immunity and ultimately, improved antitumor responses.
- 1 May 2012
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (3) , 287-357
Open AccessHuman dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity
Dendritic cell (DC) immunotherapy has shown a promising ability to promote anti-tumor immunity in vitro and in vivo. Many trials have tested single epitopes and single antigens to activate single T cell specificities, and often CD8+ T cells only. We previously found that determinant spreading and breadth of antitumor immunity correlates with improved clinical response. Therefore, to promote activation and expansion of polyclonal, multiple antigen-specific CD8+ T cells, as well as provide cognate help from antigen-specific CD4+ T cells, we have created an adenovirus encoding three full length melanoma tumor antigens (tyrosinase, MART-1 and MAGE-A6, “AdVTMM”). We previously showed that adenovirus (AdV)-mediated antigen engineering of human DC is superior to peptide pulsing for T cell activation, and has positive biological effects on the DC, allowing for efficient activation of not only antigen-specific CD8+ and CD4+ T cells, but also NK cells. Here we describe the cloning and testing of “AdVTMM2,” an E1/E3-deleted AdV encoding the three melanoma antigens. This novel three-antigen virus expresses mRNA and protein for all antigens, and AdVTMM-transduced DC activate both CD8+ and CD4+ T cells which recognize melanoma tumor cells more efficiently than single antigen AdV. Addition of physiological levels of interferon-α (IFNα) further amplifies melanoma antigen-specific T cell activation. NK cells are also activated, and show cytotoxic activity. Vaccination with multi-antigen engineered DC may provide for superior adaptive and innate immunity and ultimately, improved antitumor responses.
- 30 June 2011
- Published by Springer Nature in Immunologic Research
- Vol. 50 (2-3) , 255-260
A role for the heat shock protein–CD91 axis in the initiation of immune responses to tumors
For over 100 years, it has been established that tumor-specific immune responses can frequently be detected in the tumor-bearing host. Whether or not these immune responses are capable of controlling the growth of the tumor is influenced by many factors. However, the mechanism by which the immune responses are initiated in the first place has remained a dilemma. In this chapter, we present evidence that heat shock protein–peptide complexes released by tumor cells are the entity responsible for initiating the immune responses. Interaction of the extracellular HSP with its receptor CD91 is necessary for priming the immune response. We propose that the disruption of the HSP–CD91 interaction may be an active mechanism by which tumors prevent the generation of immune responses against it.
- 30 June 2011
- Published by Springer Nature in Immunologic Research
- Vol. 50 (2-3) , 255-260
A role for the heat shock protein–CD91 axis in the initiation of immune responses to tumors
For over 100 years, it has been established that tumor-specific immune responses can frequently be detected in the tumor-bearing host. Whether or not these immune responses are capable of controlling the growth of the tumor is influenced by many factors. However, the mechanism by which the immune responses are initiated in the first place has remained a dilemma. In this chapter, we present evidence that heat shock protein–peptide complexes released by tumor cells are the entity responsible for initiating the immune responses. Interaction of the extracellular HSP with its receptor CD91 is necessary for priming the immune response. We propose that the disruption of the HSP–CD91 interaction may be an active mechanism by which tumors prevent the generation of immune responses against it.